Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YTS109 STAR-T cell therapy in relapsed/refractory AIHA
NCT07075484Phase 1Completed
- Sponsor
- China Immunotech
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of YTS-109 in autoimmune hemolytic anemia (AIHA), sponsored by China Immunotech. Primary endpoints: Dose Limiting Toxicity at 28 days and Treatment-Emergent Adverse Events at 12 months. Started Jan 2025; status: completed.
02
Drugs
YTS-109
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07075484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07075484.